Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling.

Molecular oncology - 1 Mar 2024

Morel Marion, Long Weiwen

Abstract excerpt

Lung cancer is the leading cause of cancer-related deaths worldwide. Lung adenocarcinomas (LUADs) are a major subtype of non-small-cell lung cancers (NSCLCs). About 25% of LUADs harbor GTPase KRAS mutations associated with poor prognosis and limited treatment options. While encouraging tumor response to novel covalent inhibitors specifically targeting KRASG12C has been shown in the clinic, either intrinsic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Insulin Receptor Substrate Proteins

Share to Lung Neoplasms

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 37983945
DOI: 10.1002/1878-0261.13554
PMCID: PMC10920083

Genes

KRAS
IRS1
IGF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling.PMID 37983945Read ↗

FAM111B enhances proliferation of <i>KRAS</i>‐driven lung adenocarcinoma by degrading p16Semantic proximity Read ↗

MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells.Semantic proximity Read ↗

Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.Semantic proximity Read ↗

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.Semantic proximity Read ↗

Increased dosage of wild-type KRAS protein drives <i>KRAS</i> -mutant lung tumorigenesis and drug resistanceSemantic proximity Read ↗

Inhibition of ULK1/2 and KRAS <sup>G12C</sup> controls tumor growth in preclinical models of lung cancerSemantic proximity Read ↗

FBXL6 degrades phosphorylated p53 to promote tumor growthSemantic proximity Read ↗

LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.Semantic proximity Read ↗

RNF213 inhibits migration via mediating KRT16 ubiquitination in lung adenocarcinoma cellSemantic proximity Read ↗

Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.Semantic proximity Read ↗

Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.